Molekularpathologische Grundlagen für die Therapie des NSCLC
作者： M. Falk , C. Hallas , M. Tiemann
DOI: 10.1007/S11654-011-0335-4
关键词:
摘要: In der Behandlung solider Tumoren findet seit ca. 5 Jahren eine rasante Entwicklung, ja fast „stille Revolution“ statt. Insbesondere bei Entitaten, die mit geringer Uberlebensperspektive verbunden waren (und z. T. noch sind), bestehen zumindest fur einige Subgruppen signifikant verbesserte Moglichkeiten. Um diese Patientengruppen zu identifizieren, mussen entsprechenden genetischen Veranderungen erkannt werden.
springer.com
sci-hub.se 参考文章(30)
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
C Mascaux, N Iannino, B Martin, M Paesmans, T Berghmans, M Dusart, A Haller, P Lothaire, A-P Meert, S Noel, J-J Lafitte, J-P Sculier, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis British Journal of Cancer. ,vol. 92, pp. 131- 139 ,(2005) , 10.1038/SJ.BJC.6602258
Marc Ladanyi, William Pao, Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern Pathology. ,vol. 21, ,(2008) , 10.1038/MODPATHOL.3801018
Guang Jin, Min Jung Kim, Hyo-Sung Jeon, Jin Eun Choi, Dong Sun Kim, Eung Bae Lee, Sung Ick Cha, Ghil Sook Yoon, Chang Ho Kim, Tae Hoon Jung, Jae Yong Park, PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers Lung Cancer. ,vol. 69, pp. 279- 283 ,(2010) , 10.1016/J.LUNGCAN.2009.11.012
G. J. Riely, J. Marks, W. Pao, KRAS mutations in non-small cell lung cancer. Proceedings of the American Thoracic Society. ,vol. 6, pp. 201- 205 ,(2009) , 10.1513/PATS.200809-107LC
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
Kevin M. Sullivan, Peter S. Kozuch, Impact of KRAS Mutations on Management of Colorectal Carcinoma Pathology Research International. ,vol. 2011, pp. 219309- 219309 ,(2011) , 10.4061/2011/219309
Filip Janku, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido-Laguna, Razelle Kurzrock, PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers PLoS ONE. ,vol. 6, pp. e22769- ,(2011) , 10.1371/JOURNAL.PONE.0022769
Samuel Murray, Issa J. Dahabreh, Helena Linardou, Menelaos Manoloukos, Dimitrios Bafaloukos, Paris Kosmidis, Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database Journal of Thoracic Oncology. ,vol. 3, pp. 832- 839 ,(2008) , 10.1097/JTO.0B013E31818071F3